 |
|
|
| |
HEALTH-RELATED COSTS IN CHRONIC HIV INFECTION:
A CASE-CONTROL STUDY VS. GENERAL POPULATION USING A CLAIMS-BASED APPROACH IN GERMANY....healthcare/drug costs soar for HIV+ aging compared to HIV-neg.
|
| |
| |
Download the PDF here
Reported by Jules Levin
HIV Glasgow 2016 Oct 23-26
Eva Wolf1, Stefan Christensen2;
(1) MUC Research, Munich, Germany; (2) Center for Interdisciplinary Medicine (CIM) Infectious Diseases, Muenster, Germany
CONCLUSION
Overall, PPPY costs not related with HIV treatment (inpatient, outpatient and drug related costs not associated with ART ) are higher in the HIV cohort compared to the general population, potentially reflecting the higher burden of comorbidities observed in the HIV population (such as cardiovascular diseases, chronic renal disease and bone fractures due to osteoporosis). PPPY costs tend to increase with age for both groups, but are generally higher for HIV patients. This is particularly visible for patients over 60 years old, when the PPPY costs significantly increase for the HIV population.
Therefore, an adequate HIV management including regular monitoring, screening for comorbidities and optimal ART selection, remain critical to achieve continuous improvement of PLHIV health status and reduce the financial burden for the German healthcare system.
|
| |
|
|
|
|
|
